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ABSTRACT
Functional magnetic resonance imaging (fMRI) was used to examine functional brain
activity in two demographically matched depressed women following their participation
in a Behavioral Activation Treatment for Depression (BATD; Hopko & Lejuez, 2007) or
Pragmatic Psychodynamic Psychotherapy (PPP; Summers & Barber, 2010). A reward
responsiveness pleasurable music listening scanner paradigm was employed during brain
scanning to assess reward responsivity prior to and following treatment. Both women
responded positively to treatment, evidenced reductions in depression, and exhibited
changes in their blood oxygenation level dependence (BOLD) response as measured by
fMRI following treatment. BOLD response changes were not observed in either patient in
subcortical regions implicated in reward responsiveness following treatment. However,
BOLD response changes were observed for both patients in regions of the dorsolateral
and medial orbital prefrontal cortex and subgenual cingulate following treatment, with
each treatment affecting these areas. These findings support the notion that when BATD
and PPP are implemented effectively they are associated with functional brain changes in
areas implicated in the pathophysiology of depression.
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CHAPTER 1
INTRODUCTION
Understanding the relationship between neurobiological processes and effective
treatments for clinical depression is an important and burgeoning area of research.
Indeed, major depressive disorder is now beginning to be understood as a systems level
disorder affecting distributed regions in the cortical, subcortical, and limbic regions that
in turn contribute to the pathophysiology and symptom presentation of the condition
(Davidson Pizzagalli, Nitschke, & Putnam, 2002; Drevets, Price, & Furey, 2008;
Mayberg et al., 1997, Mayberg, 2003). Much of the aberrant functional brain activity that
characterizes depression has been normalized following recovery from depression (Brody
et al., 2001; Mayberg et al., 1999, 2000, 2005). Understanding the putative mechanisms
of change facilitated by psychosocial treatments for depression may enhance our
understanding of the pathophysiology of the disorder, lead to treatment refinement and
development, and eventually facilitate patient-treatment matching (Mayberg, 2006).
Initial studies evaluating associative changes that psychosocial treatments have on the
neurobiological basis of depression hold promise toward achieving these objectives.
Studies examining neurobiological changes associated with Interpersonal
Psychotherapy (IPT) for depression have found increased metabolic changes in the left
temporal lobe and anterior insula during resting state PET scans following treatment
(Brody et al., 2001), and increases in blood flow in the right basal ganglia and limbic
right posterior cingulate during resting state SPECT scans after six weeks of treatment
(Martin, Martin, Rai, Richardson, & Royall, 2001). Additional findings entailed
decreases in the right middle frontal gyrus (including both VLPFC and DLPFC) left
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middle anterior cingulate, and right dorsal caudate nucleus during resting state PET scan
(Brody et al., 2001). In terms of methodological limitations, results reported by Martin et
al. (2001) are somewhat limited due to the second scan occurring at 6-weeks into
treatment, mid-way through treatment completions, and because SPECT methodology
produces resolution without the precision required to evaluate activity in striatal
subregions. Nonetheless, these studies were pioneering works insofar as being among the
first to demonstrate functional brain changes corresponding to psychotherapeutic
treatments for depression.
Studies examining neurobiological changes following Cognitive Behavioral
Therapy (CBT) for depression have found increases in metabolic activity in the
hippocampus and dorsal anterior cingulate cortex (Goldapple et al., 2004), as well as
increases in the right inferior occipital cortex, left inferior temporal cortex, and anterior
portions of the subgenual/ventromedial frontal cortex during resting state PET scans
(Kennedy et al., 2007). At post-treatment, these same studies found attenuation of
depressive symptoms and decreased activations in the dorsolateral, medial, and
ventrolateral prefrontal regions, orbital frontal regions, posterior cingulate, inferior
parietal and temporal regions (Goldapple et al., 2004), as well as decreases in the bilateral
orbital frontal cortex, left medial prefrontal cortex, left dorsomedial, posterior cingulate,
and thalamus during resting state PET scans (Kennedy et al., 2007).
One study employed an affective facial processing task during fMRI scanning to
assess blood oxygenation level dependence (BOLD) prior to and following CBT for
depression, and observed elevated amygdala-hippocampal activity (relative to healthy
individuals) that was observed to normalize following treatment (Fu et al., 2008). Fu et
2

al., (2008) also observed increases in BOLD response in the dorsal anterior cingulate
following treatment. Examining reward responsiveness using a Wheel-Of-Fortune task
prior to and following Behavioral Activation Treatment for Depression (BATD; Hopko,
Lejuez, Ruggiero, & Eiffert 2003; Lejuez, Hopko, Acierno, Daughters, & Pagoto, 2011)
it was shown that simultaneous with depression symptom reduction, left planum
temporale, right superior lateral occipital cortex, and right posterior temporal fusiform
cortex functioning increased during reward feedback (Dichter et al., 2009). Following
BATD, decreases in the left posterior cingulate, left caudate, left postcentral gyrus, and
left paracingulate gyrus also were observed during reward feedback (Dichter et al., 2009).
Importantly, this was the first study using a scanner paradigm to assess neurobiological
changes directly corresponding to the aim of the treatment. Specifically, BATD was
designed to increase exposure to rewarding stimuli (Hopko et al., 2003) and the scanner
paradigm assessed for neurobiological response to rewarding feedback.
Initial findings generally suggest that positive treatment outcome among
depressed patients treated with BATD, IPT, and CBT are associated with changes in
brain regions that have been implicated in the pathophysiology of depression. Such brain
changes have been thought to reflect improved problem-solving, reductions in negative
affect and associated cognitions, decreased rumination, and improved affect regulation
and self-perception (Cabeza & Nyberg, 2000; Duncan & Owen, 2000; Northoff et al.,
2006; Ochsner & Gross, 2005). While these findings are salient to understanding the
pathophysiology of depression and the role that psychotherapeutic treatments may have
in modulating aberrant brain activations, the assumptions made about functional brain
changes are mostly based on resting state brain scans. Only two studies incorporated
3

functional tasks during brain scans to more clearly assess activations associated with
features of depression. In particular, processing affectively salient facial features (Fu et
al., 2008) and reward feedback (Dichter et al., 2009) directly relate to behavioral models
of depression and targets of intervention. Utilizing functional tasks during scanning has
been encouraged as it more clearly delineates specific neurobiological components of
depression and how treatments may or may not specifically target relevant brain regions
(Frewen, Dozois, & Lanius, 2008). Ideally, functional brain data acquired during
scanning would entail a task that is relevant to the psychiatric disorder as well as the
mechanisms of change the treatment of interest purports to be predicated upon.
Investigating neurobiological networks of reward is warranted given the relevance
of behavioral inhibition, withdrawal, avoidance, and limited behavioral activation among
depressed individuals (Jacobson, Martell, Dimidjian, 2001; Kasch, Rottenberg, Arnow &
Gotlib, 2002). Plausibly, these behavioral correlates are due to decreased reward
responsiveness as the brain activity of healthy and depressed patients are distinguishable
by differential responsiveness to rewarding stimuli. Lower activation of the mesolimbic
regions in depressed individuals is observed in response to positive stimuli such as happy
faces or pleasant autobiographical narratives (Epstein et al., 2006; Keedwell, Andrew,
Williams, Brammer, & Phillips, 2005; Schaefer, Putnam, Benca, & Davidson, 2006).
Brain regions observed to be active during passive listening to pleasurable music (Blood
& Zatorre, 2001; Menon & Levitin, 2005) have similarly been observed to be active in
response to other reward inducing stimuli such as food, sex, and drugs of abuse (Bardo,
1998; Pfaus, Damsma, Wenkstern, & Fibiger, 1995; Schilström, Svensson, Svensson, &
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Nomikos, 1998; Carelli, Ijames, & Crumling, 2000) and have distinguished brain
functioning between healthy and depressed individuals (Osuch et al., 2009).
Osuch et al., (2009) utilized a pleasurable music listening paradigm during fMRI
scanning to assess differential responsiveness to rewarding stimuli among depressed
individuals and healthy controls. Depressed individuals exhibited significantly weaker
activations in the medial orbital prefrontal cortex (moPFC) and nucleus
accumbens/ventral striatum, regions implicated in reward processing (Osuch et al., 2009).
Moreover, self-reported pleasure ratings were positively correlated with left medial
prefrontal activity and negatively correlated with the middle temporal cortex and globus
pallidus. Examining the neurobiological activity associated with reward responsiveness is
an important advancement in clarifying the pathophysiology of depression. However,
only one study has examined how such aberrant functional brain activity associated with
both diminished reward response and depressive symptoms corresponds to changes
induced by psychotherapy (Dichter et al., 2009).
Examining brain regions implicated in reward responsiveness is a pressing need,
especially given models of depression that implicate decreased behavioral activation and
minimized exposure to reward as being primary causal factors associated with the onset
and maintenance of clinical depression (Ferster, 1973; Lewinsohn, 1974; Lewinsohn &
Graf, 1973). Behavioral activation is a therapeutic process that emphasizes structured
attempts at engendering increases in overt behaviors likely to bring patients into contact
with reinforcing environmental contingencies and corresponding improvements in
thoughts, mood, and quality of life (Hopko et al., 2003). Behavioral activation
interventions largely have been used to treat depressive disorders and symptoms, with
5

three meta-analyses supporting their efficacy such that behavioral activation is now
considered an empirically validated treatment for depression (Cuijpers van Straten, &
Warmerdam, 2007; Ekers, Richards, & Gilbody, 2008; Mazzucchelli, Kane, & Rees,
2009; Sturmey, 2009). In one of the more compelling studies, behavioral activation was
comparable to antidepressant medication and superior to cognitive therapy in treating
severe depression (Dimidjian et al. 2006), results that were maintained at 2-year followup (Dobson et al., 2008). Behavioral activation also has been effectively used with
depressed patients in community mental health centers (Lejuez, Hopko, LePage, Hopko,
& McNeil, 2001; Porter, Spates, & Smitham, 2004), in a primary care setting as
administered by previously untrained mental health nurses, (Ekers, Richards, McMillan,
Bland, & Gilbody, 2011), an inpatient psychiatric facility (Hopko, Lejuez, LePage,
Hopko, & McNeil, 2003), a representative community outpatient sample (Jacobson et al.,
1996), for smokers and drug users with elevated depressive symptoms (Daughters et al.,
2008; MacPherson et al., 2010), as a single session intervention with depressed college
students (Gawrysiak, Nicholas, & Hopko, 2009), for depressed patients with obesity
(Pagoto et al., 2008) and as a supplemental intervention for patients with co-existent Axis
I (Hopko, Hopko, & Lejuez, 2004; Jakupak et al., 2006; Mulick & Naugle, 2004) and
Axis II disorders (Hopko, Sanchez, Hopko, Dvir, & Lejuez, 2003). Perhaps most relevant
to the current study, behavioral activation also has been effective with depressed cancer
patients in a medical care setting (Hopko et al., 2005, 2008, 2011), an important finding
given the high rates of depression in patients with co-existent medical problems (Welch,
Czerwinski, Chimire, & Bertsimas, 2009).
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Given the efficacy of behavioral activation in treating depression and its
purported mechanism of change being increased behavioral activation and reward
exposure, the following study was designed to evaluate whether treatment of a depressed
woman corresponded to changes in relevant functional brain activity. To examine this
question, a novel reward responsiveness paradigm (pleasurable music listening) was used
to explore regional brain activations following BATD. We first posited that music
listening was an appropriate fMRI paradigm to evaluate neurobiological reward
responsiveness given the relevant literature speaking to the relationship between music
and neurobiological activity related to reward (Blood & Zatorre, 2001; Menon & Levitin,
2005; Osuch et al., 2009). It was hypothesized that exposure to preferred as opposed to
neutral music passages at pre- and post-treatment would elicit increased activation in the
nucleus accumbens, orbital, medial, and dorsolateral prefrontal regions, ventral striatum,
and the dorsal anterior cingulate cortex, and/or reductions in the globus pallidus, the
caudate, the anterior cingulate cortex, paracingulate, posterior and subgenual cingulate
cortical regions. The second hypothesis was that following treatment these regional
changes would correspond with reduced depression severity and behavioral inhibition,
and increased environmental reward and behavioral activation.
To assess whether BATD uniquely affected regions implicated in depression and
reward responsiveness, we included a demographically matched control patient. This
patient underwent identical procedures to the patient receiving BATD with the exception
that the control patient received Pragmatic Psychodynamic Psychotherapy (PPP;
Summers & Barber, 2010), a semi-structured therapeutic intervention that utilizes
psychoanalytic principles as the primary mechanism of change (see Shedler, 2010 for a
7

review). This treatment was selected because psychodynamic treatment is garnering
increased support as an evidence-based practice that relies on mechanisms of change
quite distinct from those purported by BATD (Shedler, 2010). Accordingly, it was
predicted that functional brain changes in the control patient treated with PPP would be
distinct from those observed in the patient treated with BATD.
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CHAPTER 2
METHODS
Patients
Both patients were recruited from the University of Tennessee Medical Center’s
Cancer Institute from an on-going randomized controlled study examining the efficacy of
BATD and Problem Solving Therapy for depressed women with breast cancer (Hopko et
al., 2011). Participants for this study were recruited through physician and medical staff
referral. Eligibility criteria to participate in the present study was consistent with the
larger study and was contingent upon a primary diagnosis of major depression made by a
trained masters level clinician who administered the Anxiety Disorder Interview for
DSM-IV (ADIS-IV; Brown, Di Nardo, & Barlow, 1994). Additional eligibility
requirements included no current or former history of spinal or brain cancer, right hand
dominance as indicated by the Edinburgh Handedness Inventory (Oldfield, 1971), no
surgical metal implants, and no co-morbid Axis-I or II diagnoses other than anxiety
secondary to depression. At pre- and post-treatment evaluations, patients completed the
Behavioral Inhibition and Activation Scale (BIS/BAS; Carver & White, 1994) to assess
activity and inhibition, the Beck Depression Inventory-II (BDI-II; Beck, Steer, & Brown,
1996), to assess depression, and the Environmental Reward Observation Scale (EROS;
Armento & Hopko, 2007) to assess environmental reward. The BDI-II and EROS also
were completed after each therapy session. Clinicians completed the Hamilton Rating
Scale for Depression (HRSD; Hamilton, 1960) at pre and post-treatment.
A total of 5 patients were screened for inclusion, with two declining participation
due to time commitments and one withdrawing after inclusion due to scanner-induced
9

claustrophobia during the initial scan. This study involved inclusion of 2 patients, one
assigned to BATD and one to PPP. Both patients provided informed consent as approved
by both the University of Tennessee Graduate School of Medicine and the University of
Tennessee Institutional Review Boards.
The first patient who received BATD was a 64 year-old, right-handed, married,
Caucasian female, with two years of graduate level education. She was diagnosed with
breast cancer four months prior to her pre-assessment evaluation for study inclusion. She
received cancer treatment in the form of a lumpectomy, one month following her
diagnosis, and chemotherapy that began one month prior to study enrollment that
persisted through the course of psychotherapy. Her medication regimen was consistent
throughout therapy and was limited to allergy, migraine, and sleep prescriptions. This
patient reported no prior history of psychiatric problems other than depression and
anxiety that emerged six months prior to her cancer diagnosis due to psychosocial
stressors (i.e. death of dog, marital problems, job dissatisfaction). Her depression
significantly exacerbated upon her breast cancer diagnosis and manifested as sleep
disturbances, feelings of guilt, worthlessness and low self-esteem. Her generalized
anxiety manifested as restlessness, fatigue, difficulty concentrating, irritability, muscle
tension, and minor insomnia. At the time of inclusion in this study she was diagnosed
with major depressive disorder with generalized anxiety disorder.
The second patient who received PPP was a 68 year-old, right-handed, married,
Caucasian female, with four years of graduate school education. She was diagnosed with
breast cancer two years prior to enrollment in the study. She received cancer treatment in
the form of a left radical mastectomy approximately two years prior to study enrollment,
10

which was followed by 6 months of chemotherapy. She also received hormone treatment
(i.e., Tamoxifen) for breast cancer that persisted from one year prior to study enrollment
through mid-way through psychotherapy. Her medication regimen consisted of
prescriptions for cholesterol, hypertension, Edema, allergies, asthma, and breast cancer,
and was consistent throughout the study with the exception of Tamoxifen, which she
discontinued following consultation with her physician. This patient reported no prior
history of psychiatric problems. Her depression emerged approximately two years prior
to participation in the study and surfaced in conjunction with her cancer diagnosis and her
husband suffering a stroke. Her depression manifested as decreased energy, fatigue,
listlessness, agitation, and feeling like a failure. At the time of study inclusion she was
diagnosed with major depressive disorder.
Outcome Measures
The Hamilton Rating Scale for Depression (HRSD; Hamilton, 1960) is a 24-item
semi-structured interview designed to measure symptom severity in patients diagnosed
with depression. The instrument is the most widely used and accepted outcome measure
for the evaluation of depression and has become the standard outcome measure in clinical
trials (Kobak & Reynolds, 1999; Wolf & Hopko, 2008).
The Beck Depression Inventory-II (BDI-II; Beck et al. 1996) consists of 21 items,
each of which is rated on a 4-point Likert scale. The instrument has been demonstrated to
have excellent reliability and validity with depressed younger and older adults (Beck et
al., 1996; Dozois, Dobson, & Ahnberg, 1998). The psychometric properties of the BDI-II
have been studied in cancer patients as well as a diverse primary care sample, with the
instrument having strong predictive validity as it pertains to diagnoses of clinical
11

depression, strong internal consistency (α = .94), and adequate item-total correlations (R
= .54-.74; Arnau, Meagher, Norris, & Bramson; 2001; Katz, Kopek, Waldron, Devins, &
Thomlinson, 2004).
The Environmental Reward Observation Scale (EROS; Armento & Hopko, 2007)
is a 10-item measure (1 to 4 point Likert Scale) that assesses environmental reward and
response-contingent positive reinforcement (RCPR; Lewinsohn, 1974). Scores range
from 10 to 40, with higher scores suggesting increased environmental reward. Sample
items include “the activities I engage in usually have positive consequences,” and “lots of
activities in my life are pleasurable.” Based on psychometric research with three
independent college samples, the EROS has strong internal consistency (α = .85-.86) and
excellent test-retest reliability (r = .85), and correlates strongly with other commonly
administered and psychometrically sound self-report measures of depression (r = -.63 to .69) and anxiety (Armento & Hopko, 2007).
The Beck Anxiety Inventory (BAI; Beck & Steer, 1993) is a 21-item questionnaire
designed specifically to distinguish cognitive and somatic symptoms of anxiety from
those of depression. Good psychometric properties have been demonstrated among
community, medical, and psychiatric outpatient samples (de Beurs, Wilson, Chambless,
Goldstein, & Feske, 1997; Morin et al., 1999; Wetherell & Areán, 1997).
The Behavioral Inhibition and Behavioral Activation Scale (BIS/BAS; Kasch,
Rottenberg, Arnow & Gotlib, 2002) is a 20-item self-report questionnaire that assesses
how people typically react to certain situations. The scale is subdivided into four
subscales: Behavioral Inhibition, Behavioral Activation-Reward Responsiveness,
Behavioral Activation-Drive, and Behavioral Activation-Fun-Seeking. Internal
12

consistencies of all subscales are high (BIS = .78; BAS-RR = .80; BAS-Drive = .83;
BAS-Fun = .69). The BIS/BAS scales also have good convergent and discriminant
validity, with scores on the BAS scales typically relating to positive affect and
extraversion and scores on the BIS scale generally being related to anxiety symptoms,
negative affect and neuroticism (Carver & White, 1994; Jorm et al., 1999).
Treatments
BATD was derived from an 8-session protocol and consisted of 45–50 minute
sessions administered over 10 weeks (Hopko & Lejuez, 2007; Lejuez, Hopko & Hopko,
2001). Initial sessions consisted of assessing the function of depressed behavior, efforts to
weaken access to positive and negative reinforcement for depressed behavior, and
introduction of the treatment rationale. A systematic activation approach was then
initiated to increase the frequency and subsequent reinforcement of healthy behaviors.
The patient began with a weekly self-monitoring exercise that served as a baseline
assessment of daily activities, oriented her to the quality and quantity of her activities,
and generated ideas about activities to target during treatment. Based on a subsequent
value-based goal assessment, approximately 15 overt behaviors were identified that
would increase environmental reward and response-contingent positive reinforcement.
The overt behaviors identified in this treatment entailed increasing such things as exercise
and intimate and meaningful activities with her husband. Subsequent treatment sessions
focused on increasing engagement in rewarding activities and monitoring progress.
PPP was derived from a psychodynamic psychotherapy guide outlining case
formulations and treatment techniques (Summers & Barber, 2010), and consisted of 8 4550 minute, sessions administered over 13 weeks. PPP approach for treating depression
13

suggests two treatment goals, which are ideographically modified to meet patient
characteristics, which include: (1) decreasing vulnerability to abandonment, and (2)
decreasing harsh self-criticism (Summers & Barber, 2010). The initial phase of treatment
can be brief (e.g. 1 – 2 sessions) and in the present study was comprised of taking a
history of her depression and deciding on treatment goals: 1) working through multiple
losses and related resentment, and 2) recovering a sense of pride, resilience, and
“toughness.” Therapy proceeded in the second phase (sessions 3 - 6), toward working to
identify key themes of abandonment and loss, resentment about such loss, and conflict
over self-worth. A Core Conflictual Relational Theme (CCRT; Luborsky, 1977) was
developed, per PPP guidelines, which concretely conceptualize patient’s maladaptive
intra- and inter-personal style of relatedness. Specific discussion focuses on personal
experiences and relationships, with attention to how the past informs the present, and in
this specific treatment, how cancer and medical treatment influenced her sense of self.
The final phase of treatment draws to a close by helping the patient to consolidate new
understandings they have made.
Patients received treatment on an outpatient basis at the Cancer Institute within
the University of Tennessee Medical Center. Two advanced male clinical psychology
graduate students, similar in age and experience in their respective theoretical
orientations, conducted the therapies. Patients were scanned within one week prior to
beginning therapy and within one week following completion of therapy.
Task Design
The music listening reward responsiveness paradigm was adapted from previous
neuroimaging studies on music listening, reward, and depression (Menon & Levitin,
14

2005; Osuch et al., 2009). The paradigm was approximately 30 minutes and involved
listening to two music tracks, each of which was 7.5 minutes, followed by a 7.5-minute
period of silence to collect “resting state” data (Greicius et al., 2007). The first track was
comprised of 50 seconds of preferred music, 50 seconds of neutral music, then 50
seconds of silence. This sequence repeated twice more proceeding through the respective
songs in 50-second segments totaling 7.5 minutes for the first track. The second track was
identical with the exception of the order of preferred and neutral music being reversed
(see Figure 1 for visual representation of block design). Track order was reversed for
time 2 such that tracks began with the neutral stimulus if the previous scan began with the
preferred stimulus. Patients were also counterbalanced to order such that for the first scan
one patient heard her preferred passage first where the other heard the neutral first.
Selection of preferred and neutral music passages was based on previously
established methodology (Osuch et al., 2009) whereby prior to the day of the scan,
patients listened to numerous instrumental music passages that they rated on a likert scale
ranging from -100 (disliked completely) to 0 (neither liked nor disliked) to +100 (liked
completely). Rankings were obtained in intervals of 20 and considered neutral if rated
between -40 through +40 and preferred if rated 60 or higher. The neutral music passage
served as the control condition for brain activity associated with a non-rewarding
stimulus. Volume and clarity of music was assessed prior to scanning to ensure each
patient could hear music passages. Patients were given no instructions during scanning
other than to stay focused and remain still.
Functional MRI Acquisition
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Imaging was performed on a 1.5-T Siemens MRI scanner with a standard head coil at the
University of Tennessee Department of Radiology. In each condition, 150 whole-brain
functional T2*-weighted echo planar images were acquired, each comprising 35 slices
parallel to the intercommissural (AC-PC) line: repetition time (TR) 3000 ms; echo time
(TE) 50 ms; flip angle 90º; slice thickness 3.75 mm; matrix 64 x 64; field of view (FOV)
220mm x 220mm for a voxel size of 3.44 x 3.44 x 3.75 mm^3.
Functional MRI Pre-Processing
Data processing took place using Statistical Parametric Mapping (SPM8) methods
(Wellcome Department of Cognitive Neurology, London, United Kingdom). Highresolution anatomical images were registered nonlinearly to the ICBM atlas space using
the MNI-152 templates. Each volume of the fMRI image series was aligned to the first
using rigid body registration to correct for head motion. Then the high-resolution
anatomical image was rigidly registered with the first functional, and the nonlinear
transformation to atlas space was applied to all functional images. Images were
subsequently smoothed using a 6 mm FWHM Gaussian kernel.
Functional MRI Statistical Analysis
Statistical parametric mapping was also performed using SPM8 software. Preand post-treatment scans were included in a single massively univariate general linear
model. Regressors were included for each condition (neutral or preferred) to indicate
music listening for each run of each session. These images consist of appropriate boxcar
functions convolved with a canonical hemodynamic response shape. Within each session
the contrast of BOLD signal during the preferred music relative to the neutral music run
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was used as a measure of brain response to reward. This measure was compared between
sessions using relevant contrasts to examine the effect of treatment.
The SPM T maps of the contrast of interest were set at a threshold of T=2.58
(voxelwise p<0.005). The statistical significance of the resulting clusters was calculated
using the approach of random field theory (Worsley, 1994; Friston, Worsley,
Frackowiak, Mazziotta, & Evans, 1994). With knowledge of the search volume (number
of total voxels) and the smoothness of the T map images, this methodology allows for
calculating the probability of a suprathreshold cluster of a particular size occurring by
chance. To improve sensitivity, this statistical analysis was limited to an a priori region of
interest using small volume correction methodology (Friston, 1997). By limiting the
volume searched to only part of the brain, the statistical corrections applied can be less
stringent, allowing better sensitivity to small changes at the cost of missing activations
outside the a priori region. The regions of interest included brain areas related to reward
responsiveness and depression treatment outcome and was defined as the union of
caudate, putamen, pallidum, accumbens, anterior cingulate, paracingulate, orbital frontal
cortex, subcallosal, medial frontal, posterior cingulate, middle, inferior (opercularis,
triangularis), and superior frontral gyrus, and the frontal pole, from the Harvard-Oxford
probabilistic atlas implemented in FSLView v3.0
(http://www.fmrib.ox.ac.uk/fsl/fslview/index.html). Clusters that showed significant
responses at the uncorrected cluster-level p-value of 0.05 were tabulated and reported
along with p-values corrected for multiple comparisons at the whole brain level.
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CHAPTER III
RESULTS
Clinical Data
Clinically relevant changes were observed in both treatments as evidenced by
reductions in behavioral measures from pre- to post-treatment assessment (see Table 1).
The patient treated with BATD exhibited depressive symptom reduction based on a
change in her BDI-II score from 24 (moderate depression) to 2 (no depression), a
reduction on her HRSD from 26 to 0, and increased environmental reward on the EROS
(21 to 26). The patient receiving PPP also demonstrated clinically significant reductions
in depression [BDI-II scores from 31 (severe depression) to 3 (no depression), HRSD
from 21 to 3] and increased environmental reward on the EROS (18 to 30). Both patients
exhibited an increase in environmental reward and a decrease in depressive symptoms
throughout the course of treatment as evidenced by self-report measures completed at
pre-treatment assessment, at each therapy session, and at post-treatment assessment (see
Figures 2-5). Minimal symptom change was observed on self-report measures of anxiety
or BIS/BAS scores, however, as indicated in Table 1.
To further assess changes observed in measures of depression and environmental
reward, a cross-correlation analyses (CCA) was conducted using the Simulation
Modeling Analysis software (SMA; Borckardt, 2006) to determine the extent to which
changes in weekly session measures were related to one another throughout therapy.
CCA determines the degree that two variables are related to each other at a specified
interval. For both cases, the two measures were most highly correlated at lag 0, meaning
that BDI-II scores were most strongly related to EROS scores on a session-by-session
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basis. CCA statistics for the patient receiving BATD showed that the BDI-II and EROS
scores were statistically significant at lag 0 (r = -0.92, p = 0.000; see Figure 6) likewise
the patient receiving the PPP treatment was statistically significant at lag 0 (r=-0.90, p =
0.001; see Figure 7).
Functional MRI Data
To assess changes in BOLD response following treatment, contrasts were run
with a basic subtraction method where an uncorrected p-value (< 0.05) was applied.
Assessment of BOLD responses was done through two types of contrast. The first
contrast was time (pre-treatment, post-treatment) by music (preferred, neutral) to assess
responsiveness to preferred relative to neutral music. The second contrast examined time
(pre-treatment, post-treatment) by music, disregarding preference (music, silence) to
assess responsiveness to music relative to silence. Examination of both contrasts revealed
no changes in any of the sub-cortical regions implicated in reward responsiveness
hypothesized to change following treatment. Neither contrast revealed significant BOLD
responses within the nucleus accumbens, caudate nucleus, ventral striatum, anterior
cingulate, the posterior cingulate, or the globus pallidus in either patient.
Contrasts examining music valence, preferred and neutral, did not result in
significance at the p-corrected level for any regions but did evidence significance in
several regions at the p-uncorrected level (See Tables 2 & 3). Contrasts that resulted in
significance at the p-corrected value examined music and silence and evidenced
significant changes in two different brain regions (See Tables 2 & 3). Common to both
treatments were changes observed within the subgenual cingulate. The patient receiving
BATD exhibited elevated subgenual cingulate BOLD response during silence at pre19

treatment and reduced BOLD response at post-treatment, where activity was not
distinguishable between music and silence (See Figure 9). The PPP condition also
exhibited changes in the subgenual cingulate region such that BOLD response here was
observed to be elevated during music at pre-treatment, and to become elevated during
silence at post-treatment (See Figure 11). The PPP condition was also associated with
post-treatment significance, at the p-corrected level, within the superior frontal gyrus.
BOLD response here was observed to be elevated during music at pre-treatment and was
reduced during music at post-treatment, or rather, elevated BOLD response during
silence at post-treatment (See Figure 11).
Contrasts examining music preference over neutral did not result in significance
at the p-corrected level for any regions. However, several regions evidenced significance
at the p-uncorrected level and are reported here. While these data are not significant at the
p-corrected level, they may be suggestive of certain patterns of activation relevant to the
pathophysiology of depression and treatment and are therefore reported. Common to both
treatments, changes were observed in bilateral dorsolateral prefrontal regions (dlPFC),
and the medial orbital prefrontal regions (moPFC), with each treatment differentially
affecting these regions (see Tables 2 & 3). Within the BATD condition, pre- to posttreatment responses during the preferred relative to neutral music contrast resulted in
increased BOLD response activations in the bilateral moPFC and right dlPFC/frontal eye
field (see Figure 8). When comparing the interaction between pre- and post-treatment
with music and silence, the BATD condition resulted in BOLD response increases in the
right moPFC and deactivations in the left lateral anterior frontal cortex (see Figure 9).
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BOLD responses in the left dlPFC were deactivated during music at pre-treatment and
indistinguishable between music and silence at post-treatment (see Figure 9).
Within the PPP condition, pre- to post-treatment responses during the preferred
relative to neutral music contrast resulted in increased BOLD response activations in the
right moPFC and deactivations in left and right dlPFC relative to neutral music passages.
(see Figure 10). When comparing the interaction between pre- and post-treatment with
music and silence, the PPP condition resulted in BOLD response deactivations in the left,
lateral orbital PFC and the dlPFC/frontal eye field (see Figure 11).
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CHAPTER IV
DISCUSSION
This study explored changes in depression symptom severity and functional brain
activation following 8 sessions of two psychosocial treatments for clinical depression.
Both patients responded favorably to respective treatments, as reflected on both clinician
and self-report measures of depression. A direct inverse relation between self-reported
depression and environmental reward, with depression attenuation associated with
increased environmental reward supports predominant behavioral models of depression
(Carvalho & Hopko, 2011; Lewinsohn, 1974; Manos, Kanter, & Busch, 2010). Neither
patient evidenced substantial changes in self-reported behavioral inhibition or behavioral
activation, however, providing no support for the hypothesis that functional brain
changes would correspond to changes on behavioral inhibition and activation.
Our first hypothesis was unsupported as the music listening fMRI paradigm did
not sufficiently elicit activity in subcortical regions implicated in reward. No contrast
revealed significant changes in the several hypothesized regions implicated in reward
responsiveness and depression. To speculate on this finding, either the rewarding music
paradigm was insufficient to elicit reward responsiveness and corresponding neural
underpinnings or the small sample size restricted the power necessary to observe changes
in these subcortical areas. The latter explanation is suspected as very similar scanner
paradigms have been previously employed and demonstrated efficacy in eliciting reward
responsiveness neural activity in both healthy controls and depressed individuals (Osuch
et al., 2009). A third possibility is that BATD and PPP do not exert their neurobiological
mechanism of change via direct effect on subcortical neural circuits of reward, and that
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these regions are affected as a secondary consequence of frontal cortical regions being
engaged during psychotherapy.
Regarding the contrast examining music and silence, statistically significant
changes at the p-corrected level emerged in two different regions. First, activity in
regions within, or in close proximity to, the subgenual cingulate was significant for both
patients. BOLD signal response for the BATD patient was observed to be elevated during
silence relative to music at pre-treatment, and was observed to attenuate and become
indistinguishable between music and silence at post-treatment. Elevated activity here has
been observed to be a hallmark for neurobiological models of depression (Mayberg et al.,
1999, 2000, 2005; Mayberg 2006), and generally is abnormally elevated among
depressed individuals during resting-state scans (Greicius et al., 2007). Data from
numerous studies utilizing neuroimaging modalities to evaluate differing mood states
implicate the subgenual cingulate as a brain region crucial to emotion processing and to
the pathophysiology of mood disorders (Mayberg et al., 2005; Greicius, et al., 2007). The
attenuation of subgenual cingulate activity following BATD taken in conjunction with
other cortical findings may reflect a biological mechanism of change where the patient
was better able to modulate her emotional experiences, thereby enhancing her capacity to
enjoy pleasurable stimuli. In either case, subgenual cingulate activity is elevated in
depressed states (Drevets, Bogers, & Raichle, 2002; Kennedy et al., 2001) and tends to
decline in activity in depressed patients who respond to treatment (Kennedy et al., 2001;
Mayberg et al., 2000). A seemingly opposite pattern was observed within the subgenual
cingulate for the PPP patient. BOLD response was elevated during music relative to
silence at pre-treatment, and was deactive during music relative to neutral at post23

treatment. Simply stated, BOLD response within the subgenual cingulate increased
during neutral music following PPP treatment. This is difficult to interpret in lieu of the
patient’s reduction in depressive symptoms and requires experimental replication.
Significance, at the p-corrected level, was also observed in the superior frontal
gyrus for the PPP condition. This area evidenced elevated BOLD response during music
compared to silence at pre-treatment and attenuated BOLD response at post-treatment
during music, such that it was elevated during silence. This region has been observed to
play a role in executive functioning, affect regulation, self-reference, and laughter among
other things (Fried, Wilson, MacDonald, & Behnke, 1998; Goldberg, Harel, Malach,
2006; Koenigs & Gragman, 2009). Interestingly, regional decreased activity within this
region and in immediately surrounding regions, is associated with depression (Koenigs &
Grafman, 2009) where increased metabolism here has been associated with recovery
from depression (Mayberg et al., 1997). The fact that this region increased BOLD signal
during silent conditions may reflect increased cognitive processes that was adaptive and
consistent with reduction in depression.
Of note, several other brain regions evidenced BOLD response that was
interesting and deserving of speculation despite their not achieving statistical significance
at the p-corrected level. We feel compelled to report additional results that were observed
at the p-uncorrected level as these regions were part of our a priori predictions, BOLD
response changes were observed within similar regions for both patients, and because
these regions are implicated in the pathophysiology of depression (Mayberg 2003, 2006).
While these results are speculative, we suspect that, with a larger sample size, many of
these regions would have reached statistical significance at the p-corrected level.
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Contrasts examining music preference over neutral resulted in significance at the
p-uncorrected value in several regions which, although highly speculative, may be
suggestive of certain patterns of activation relevant to the pathophysiology of depression
and our treatment. Both treatments evidenced differential changes within similar regions
of interest. For example, BOLD response in the right dlPFC was observed to increase
activation during preferred relative to neutral music in the BATD condition, where
bilateral dlPFC was observed to trend towards deactivation during preferred music in the
PPP condition. Similar findings were observed with music and silence for left sided
dlPFC where increased BOLD response was observed in the BATD condition in response
to music where it was observed to attenuate in response to music for the PPP condition.
These findings suggest that bilateral dlPFC increases in BOLD response for preferred
music relative to neutral and silence conditions for the BATD patient, where the opposite
pattern was observed for the PPP patient.
The dlPFC has commonly been associated with “cognitive” or “executive”
functions where hypoactivity has been commonly observed in depressed individuals with
increased activity reflecting attenuations in depressive symptoms (Koenigs & Grafman,
2009). One interpretation, while highly speculative, might be that BATD resulted in
reduced depression severity, thereby allowing the BATD patient to more effectively and
efficiently utilize cognitive resources to more effectively cope with depression (Eysenck
& Calvo, 1992). This increased dlPFC activation was seemingly not at the expense of
experiencing pleasureable music stimuli, as post-treatment scans revealed elevated
BOLD responses in the moPFC for preferred relative to neutral music.
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Interestingly, while hypoactivity in the dlPFC is observed in depression,
decreased glucose metabolism has been observed following CBT and IPT treatment for
depression (Brody et al., 2001; Goldapple et al., 2004). Therefore, one speculation of the
dlPFC deactivations observed in the PPP patient might be that treatment resulted in a
reduction in ruminative depressive affect during passive experiences whereby in the
patient’s ability to enjoy pleasureable music was enhanced. This is one plausible
interpretation as the post-treatment assessment revealed BOLD signal response within the
moPFC to increase, while the dlPFC decreased. In either case, both treatments resulted in
symptom reduction, and increased activation in the moPFC during preferred music
passages at post-treatment. The moPFC is a region that has shown to be correlated with
pleasure ratings of music (Osuch et al., 2009). These disparate findings may plausibly
reflect differential neural mechanisms of change induced by different treatment
approaches.
Consistent with a priori hypotheses, activity within bilateral regions of the medial
orbital frontal cortex increased during preferred music following BATD treatment. Rightsided activations in this region also became more active for music relative to silence at
post-treatment. This region has been implicated in models of depression (Mayberg 2003,
2006), and distinguishes depressed and healthy individuals during music listening tasks
(Osuch et al., 2009). Change observed in the BATD patient might plausibly reflect an
increased capacity to experience reward as the moPFC plays a role in relative rather than
absolute reward (Elliott, Agnew & Deakin, 2008). These bilateral elevations in the
moPFC may reflect a greater ability of the BATD patient’s capacity to experience
pleasure as this region has been implicated in a conscious regulation of emotional states
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(Phillips, Drevets, Rauch, & Lane, 2003). The PPP patient also experienced a somewhat
similar activation pattern of right sided medial orbital activity that involved increased
BOLD signal response for preferred relative to neutral music at post-treatment. We
speculate that these regional activations might reflect an increased capacity to experience
affectively arousing music during scanning. It is difficult to state this with confidence,
however, as our results are interpreted based of p-uncorrected values and are derived
from a sample size of 1 patient per treatment.
Importantly, within all contrasts examined, similarities were not noted with those
reported in other studies examining BOLD responses to reward responsiveness following
BATD (Dichter et al., 2009). Our interpretation of the distinct findings observed is that
we employed a relatively simple reward response paradigm that assessed a more passive
pleasurable experience, rather than a more sophisticated reward paradigm that required
engagement in tasks to elicit components related to reward selection, feedback and
response (Smoski et al., 2009). Moreover, this study assessed BOLD response change
and depression symptom attenuation among two patients, a very small sample size that
might have restricted power to detect changes in sub-cortical regions implicated in
reward responsiveness.
Although this study demonstrated functional brain changes assessed by fMRI
BOLD response, several limitations must be addressed. First, due to the small sample
size, this study requires replication to assess external validity. Second, changes were
assessed between two patients receiving disparate interventions for depression, with
neural changes interpreted based on intervention characteristics. In addition to a larger
sample size, a stronger research design would include a no-treatment control group to
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control for the passage of time in the attenuation of depressive symptoms or changes in
functional brain activity. Furthermore, neither treatment was independently evaluated to
measure and assess therapist competence or treatment adherence. Third, although both
treatments demonstrated efficacy in ameliorating depression, the PPP patient data may be
somewhat confounded by the discontinuation of Tamoxifen, a hormone treatment for
breast cancer that has depression listed as a side-effect for 15% of women (Demissie,
Silliman, & Lash, 2001). It can therefore not be ruled out that attenuation in depressive
symptoms and corresponding changes in neurobiological activity observed from pre- to
post-treatment was due in some part to hormone fluctuation. Likewise, it is not clear to
what extent the consistent regimen of allergy and sleep medication constitutes and artifact
for each patient’s depression, their respective treatments, or the results of their brain
scans. Finally, while attempts were made to include participants that matched as close as
possible, important differences deserve mention. Patient differences included co-morbid
psychiatric diagnosis of generalized anxiety disorder for the BATD patient who
evidenced slightly elevated BAI at pre-treatment that did not attenuate following
treatment. Moreover, both patients were also in substantially different stages of the
cancer treatment and recovery such that the patient receiving PPP was two years cancer
remised where the BATD patient was in the midst of her chemotherapy treatment.
While the music paradigm used in this study did not effectively elicit subcortical
activations associated with reward responsiveness, it did effectively elicit cortical
activations, at the p-uncorrected level, implicated in reward, affect regulation, and
executive function. It is therefore a viable scanner paradigm that should be employed in
future studies using larger samples of depressed individuals. Moreover, this is the second
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study demonstrating that when BATD is associated with positive treatment outcome,
functional brain changes are identified. This was also the first study assessing PPP and
associated functional brain changes. While these results are preliminary, this study may
be suggestive that while two treatment approaches may effectively attenuate symptoms of
depression, they may do so through distinct neurobiological mechanisms. This bares
relevance as the pathophysiology of depression is hypothesized to be a neural network
distributed through cortical and subcortical regions of the brain with differential
components of the network playing roles in subtypes of depression (Mayberg, 2003,
2006). Future studies might consider evaluating how different treatment approaches
differentially target specific neural components of depression. The future treatment of
psychiatric disorders may greatly benefit from basing treatment selections on
neurobiological features that are known to respond more to one treatment relative to other
available options.

29

LIST OF REFERENCES

30

Armento, M. E. A., & Hopko, D. R. (2007). The environmental reward observation scale
(EROS): Development, validity, and reliability. Behavior Therapy, 38, 107-119.
Armento, M. E. A., & Hopko, D. R., (2009). Behavioral activation of a breast cancer
patient with coexistent major depression and generalized anxiety disorder.
Clinical Case Studies, 8, 25-37.
Arnau, R. A., Meagher, M. W., Norris, M. P., & Bramson, R. (2001). Psychometric
evaluation of the Beck Depression Inventory-II with primary care medical
patients. Health Psychology, 20, 112-119.
Bardo, M. T. (1998). Neuropharmacological mechanisms of drug reward: Beyond
dopamine in the nucleus accumbens. Critical Reviews in Neurobiology, 12(1-2),
37-67.
Beck, A. T., & Steer, R. A. (1993). Beck Anxiety Inventory: Manual. San Antonio, TX:
The Psychological Corporation.
Beck, A. T., Steer, R. A., & Brown, G. K. (1996). Manual for the BDI-II. San Antonio,
TX: The Psychological Corporation.
Blood, A. J., & Zatorre, R. J. (2001). Intensely pleasurable responses to music correlate
with activity in brain regions implicated in reward and emotion. Proceedings for
the National Academy of the Sciences U.S.A., 98(20), 11818 – 11823.
Borckardt, J.J., Nash, M.R., Murphy, M. D., Moore, M., Shaw, D., & O-Neil, P. (2008).
Clinical practice as natural laboratory for psychotherapy research. American
Psychologist, 63, 77-95.

31

Brody, A. L., Saxena, S., Stoessel, P., Gillies, L. A., Fairbanks, L. A., Alborzian, B. S.,…
Baxter, L. R. (2001). Regional brain metabolic changes in patients with major
depression treated with either paroxetine or interpersonal therapy: Preliminary
findings. Archives of General Psychiatry, 58, 631-640.
Brown, T. A., Di Nardo, P., & Barlow, D. H. (1994). Anxiety disorders interview
schedule for DSM-IV. SanAntonio, TX: The Psychological Corporation.
Cabeza, R., & Nyberg, L. (2000). Imaging cognition II: An empirical review of 275 PET
and fMRI studies. Journal of Cognitive Neuroscience, 12, 1-47.
Carelli, R. M., Ijames S., Crumling, A. (2000) Evidence that separate neural circuits in
the nucleus accumbens encode cocaine versus ‘natural’ (water and food) reward,
The Journal of Neuroscience, 20(11), 4255-4266.
Carvalho, J. P., & Hopko, D. R. (2011). Behavioral theory of depression: Reinforcement
as a mediating variable between avoidance and depression. Behavior Therapy and
Experimental Psychiatry, 42, 154-162.
Carver, C. S., & White, T. L. (1994). Behavioral inhibition, behavioral activation, and
affective responses to impending reward and punishment: The BIS/BAS scales.
Journal of Personality and Social Psychology, 67, 319-333.
Cuijpers, P., van Straten, A., & Warmerdam, L. (2007). Behavioral activation treatments
of depression: A meta-analysis. Clinical Psychology Review, 27, 318-326.
Daughters, S. B., Braun, A. R., Sargeant, M. N., Reynolds, E. K., Hopko, D. R.,
Blanco,… Lejuez, C. W. (2008). Effectiveness of a brief behavioral treatment for
inner-city illicit drug users with Elevated depressive symptoms: The Life
Enhancement Treatment for Substance Use (LETS ACT!). Journal of Clinical
32

Psychiatry, 69, 122-129.
Davidson, R. J., Pizzagalli, D., Nitschke, J. B., & Putnam, K. P. (2002). Depression:
Perspectives from affective neuroscience. Annual Review of Psychology, 52, 545575.
de Beurs, E., Wilson, K. A., Chambless, D. L., Goldstein, A. J., & Feske, U. (1997).
Convergent and divergent validity of the Beck Anxiety Inventory for patients with
panic disorder and agoraphobia. Depression and Anxiety, 6, 140-146.
Dichter, G. S., Felder, J. N., Petty, C., Bizzell, J., Ernst, M., & Smoski, M. J. (2009). The
effects of psychotherapy on neural responses to rewards in major depression.
Biological Psychiatry, 1(66), 886-897.
Dimidjian, S., Hollon, S., Dobson, K., Schmaling, K., Kohlenberg, B., Addis, M.
E.,…Jacobson, N.S. (2006). Randomized trial of behavioral activation, cognitive
therapy, and antidepressant medication in the acute treatment of adults with major
depression. Journal of Consulting and Clinical Psychology, 74, 658–670.
Dimissie, S., Silliman, R. A., & Lash, T. L. (2001). Adjuvant tamoxifen: Predictors of
use, side effects, and discontinuation in older women. Journal of Clinical
Oncology, 19(2), 322-328.
Dobson, et al. (2008). Randomized trial of behavioral activation, cognitive therapy, and
antidepressant medication in the prevention of relapse and recurrence in major
depression. Journal of Consulting and Clinical Psychology. 76, 468-477.
Dozois, D. J., Dobson, K. S., & Ahnberg, J. L. (1998). A psychometric evaluation of the Beck
Depression Inventory-II. Psychological Assessment, 10, 83-89
Drevets, W. C., Bogers, W., & Raichle, M. E. (2002). Functional anatomical correlates of
33

antidepressant drug treatment assessed using PET measures of regional glucose
metabolism. European Neuropsychopharmacology, 12, 527-544.
Drevets, W. C., Price, J. L., & Furey, M. L. (2008). Brain structural and functional
abnormalities in mood disorders: Implications for neurocircuitry models of
depression. Brain Structure and Function, 213(1-2), 93-118.
Duncan, J., & Owen, A. M. (2000). Common regions of the human frontal lobe recruited
by diverse cognitive demands. Trends in Neurosciences, 23, 475-483.
Ekers, D. Richards, D. & Gilbody, S. (2008). A meta-analysis of randomized trials of
behavioural treatment of depression. Psychological Medicine, 38(5) 611-623.
Ekers, D., Richards, D, McMillan, D., Bland, J. M., & Gilbody, S. (2011). Behavioral
activation delivered by the non-specialist: Phase II randomized controlled trial.
The British Journal of Psychiatry,198, 66-72.
Elliott, R., Agnew, Z., & Deakin, J. F. (2008). Medial orbitofrontal cortex codes relative
rather than absolute value of financial rewards in humans. European Journal of
Neuroscience, 27, 2213-2218.
Epstein, J., Pan, J., Kosis, J.J., Yang, Y., Butler, T., Chusid, J.,…Silbersweig, D.A.
(2006). Lack of ventral striatal response to positive stimuli in depressed versus
normal subjects. American Journal of Psychiatry, 163, 1784-1790.
Eysenck, M.W., & Calvo, M.G. Anxiety and performance: The processing efficiency
theory. Cognition and Emotion, 6, 409-434
Ferster, C. B. (1973). A functional analysis of depression. American Psychologist, 28,
857–870.

34

Fu, C. H., Williams, S. C., Cleare, A. J., Scott, J., Mitterschiffthaler, M. T., Walsh, N.
D.,…Murray, R. M. (2008). Neural responses to sad facial expressions in major
depression following cognitive behavioral therapy. Biological Psychiatry, 64,
505-512.
Frewen, P. A., Dozois, D. J. A., Lanius, R. A. (2008). Neuroimaging studies of
psychological interventions for mood and anxiety disorders: Empirical and
methodological review. Clinical Psychology Review, 28, 228-246.
Fried, I., Wilson, C., MacDonald, K., & Behnke, E. (1998). Electric current stimulates
laughter, Nature, 391, 650.
Friston, K. J. (1997). Testing for anatomically specified regional effects. Human Brain
Mapping, 5, 133-136, 1997.
Friston, K. J., Worsley R. S. J., Frackowiak, J. C. Mazziotta, & Evans, A. C. (1994).
Assessing the significance of focal activations using their spatial extent. Human
Brain Mapping, 1, 214-220, 1994.
Gawrysiak, M., Nicholas, C., & Hopko, D.R. (2009). Behavioral activation for moderately
depressed university students: Randomized controlled trial. Journal of Counseling
Psychology, 56, 468-475.
Goldapple, K., Segal, Z., Garson, C., Lau, M., Bieling, P., Kennedy, S., & Mayberg, H.
S. (2004). Modulation of cortical-limbic pathways in major depression:
Treatment-specific effects of cognitive behavior therapy. Archives of General
Psychiatry, 61, 34-41.
Goldberg I., Harel, M., & Malach, R. (2006). When the brain loses its self: prefrontal
inactivation during sensorimotor processing. Neuron, 50(2), 329–39.
35

Greicius, M.D., Flores, B.H., Menon, V., Glover, G.H., Solvason, H.B., Kenna, H.,..
Schatzberg, A.F. (2007). Resting-state functional connectivity in major
depression: Abnormal contributions from subgenual cingulated cortex and
thalamus. Biological Psychiatry, 62, 429-437.
Hamilton, M. (1960). A rating scale for depression. Neurology, Neurosurgery and
Psychiatry, 23, 56-61.
Hollon, S. D. (2001). Behavioral activation treatment for depression: A commentary.
Clinical Psychology: Science and Practice, 8, 271–274.
Hopko, D. R., Armento, M. E. A, Robertson, S. M. C, Ryba, M., Carvalho, J. P.,
Johanson, L.,…Lejuez, C.W. (2011). Brief behavior activation and problemsolving therapy for depressed breast cancer patients: Randomized controlled trial,
Manuscript submitted for publication.
Hopko, D. R., Bell, J. L., Armento, M. E. A., Hunt, M. K., & Lejuez, C. W. (2005).
Behavior therapy for depressed cancer patients in primary care. Psychotherapy:
Theory, Research, Practice, Training, 42, 236–243.
Hopko, D. R., Hopko, S. D., & Lejuez, C. W. (2004). Behavioral activation as an
intervention for co-existent depressive and anxiety symptoms. Clinical Case
Studies, 3, 37-48.
Hopko, D. R., Bell, J., Armento, M. E. A., Robertson, S. M. C., Mullane, C., Wolf, N. J.,
& Lejuez, C. W. (2008). Cognitive-behavior therapy for depressed cancer patients
in a medical care setting. Behavior Therapy, 39, 126-136.
Hopko, D. R., & Lejuez, C. W. (2007). A cancer patient's guide to overcoming
depression and anxiety: Getting through treatment and getting back to your life.
36

Oakland, CA: New Harbinger.
Hopko, D. R., Lejuez, C. W., LePage, J., Hopko, S. D., & McNeil, D. W. (2003). A brief
behavioral activation treatment for depression: A randomized trial within an
inpatient psychiatric hospital. Behavior Modification, 27, 458-469.
Hopko, D. R., Lejuez, C. W., Ruggiero, K. J., & Eifert, G. H. (2003). Contemporary
behavioral activation treatments for depression: Procedures, principles, progress.
Clinical Psychology Review, 23, 699-717.
Hopko, D. R., Robertson, S. M. C., & Colman, L. (2009). Behavioral activation therapy
for depressed cancer patients: Factors associated with treatment outcome and
attrition. The International Journal of Behavioral Consultation and Therapy, 4,
319-327.
Hopko, D. R., Sanchez, L., Hopko, S. D., Dvir, S., & Lejuez, C. W. (2003). Behavioral
activation and the prevention of suicide in patients with borderline personality
disorder. Journal of Personality Disorders, 17, 460–478.
Jacobson, N. S., Dobson, K. S., Truax, P. A., Addis, M. E., Koerner, K., Gollan, J.
K.,…Prince, S. E. (1996). A component analysis of cognitive-behavioral
treatment for depression. Journal of Consulting and Clinical Psychology, 64, 295304.
Jacobson, N.S., Martell, C.R., Dimidjian, S., (2001). Behavioral activation treatment for
depression: Returning to contextual roots. Clinical Psychology: Science and
Practice 8, 255-270.
Jakupak, M., Roberts, L., Martell, C., Mulick, P., Michael, S., Reed, R.,…McFall, M.
(2006). A pilot study of behavioral activation for veterans with
37

posttraumaticstress disorder. Journal of Traumatic Stress, 19, 387-391.
Jorm, A. F., Christensen, H., Henderson, A. S., Jacomb, P. A., Korten, A. E., & Rodgers,
B. (1999). Using the BIS/BAS scales to measure behavioural inhibition and
behavioural activation: Factor structure, validity and norms in a large community
sample. Personality and Individual Differences, 26(1), 49–58.
Kasch, K.L., Rottenberg, J., Arnow
, B.A., & Gotlib, I.H. (2002). Behavioral activation and inhibition systems and the
severity and course of depression. Journal of Abnormal Psychology, 111, 589597.
Katz, M. R., Kopek, N., Waldron, J., Devins, G. M., & Thomlinson, G. (2004). Screening
for depression in head and neck cancer. Psycho-Oncology, 13, 269-280.
Keedwell, P. A., Andrew, C., Williams, S. C., Brammer, M. J., & Phillips, M. L. (2005).
The neural correlates of anhedonia in major depressive disorder. Biological
Psychiatry, 59, 843-853.
Kennedy, S. H., Evans, K. R., Kruger, S., Mayberg, H. S., Meyer, J. H., McCann,
S.,…Vaccarino, F. J. (2001). Changes in regional brain glucose metabolism
measure with positron emission tomorgraphy after paroxetine treatment of major
depression. American Journal of Psychiatry, 158, 899-905.
Kennedy, S. H., Konarski, J. Z., Segal, Z. V., Lau, M. A., Bieling, P. J., McIntyre, R. S.,
& Mayberg, H. S. (2007). Differences in brain glucose metabolism between
responders to CBT and venlafaxine in a 16-week randomized controlled trial.
American Journal of Psychiatry, 164, 778-788.

38

Kobak, K. A., & Reynolds, W. M. (1999). Hamilton Depression Inventory. In M. E.
Maruish (Ed.), The use of psychological testing for treatment planning and
outcomes assessment (2nd Edition, pp. 935-969). Mahwah, NJ: Lawrence
Erlbaum.
Koenigs, M. & Grafman, J. (2009). The functional neuroanatomy of depression: Distinct
roles for ventromedial and dorsolateral prefrontal cortex. Behavioural Brain
Research, 201, 239-243.
Lejuez, C. W., Hopko, D. R., & Hopko, S. D. (2001). A brief behavioral activation
treatment for depression: Treatment manual. Behavior Modification, 25, 255–286.
Lejuez, C. W., Hopko, D. R., & Hopko, S. D. (2002). The brief behavioral activation
treatment for depression (BATD): A comprehensive patient guide. Boston, MA:
Pearson Custom Publishing.
Lejuez, C. W., Hopko, D. R., Acierno, R., Daughters, S. B., & Pagoto, S. (in press). The
Behavioral Activation Treatment for Depression (BATD-R): Revised treatment
manual. Behavior Modification.
Lejuez, C. W., Hopko, D. R., LePage, J., Hopko, S. D., & McNeil, D. W. (2001). A brief
behavioral activation treatment for depression. Cognitive and Behavioral
Practice, 8, 164–175.
Lewinsohn, P. M. (1974). A behavioral approach to depression. In R. M. Friedman and
M. M. Katz (Eds.), The psychology of depression: Contemporary theory and
research. (pp. 157-178). Oxford, England: John Wiley & Sons.
Lewinsohn, P. M., & Graf, M. (1973). Pleasant activities and depression. Journal of
Consulting and Clinical Psychology, 41, 261–268.
39

MacPherson, L., Tull, M. T., Matusiewicz, A. K., Rodman, S., Strong, D. R., Kahler,
C….Lejuez, C. W. (2010). Randomized controlled trial of behavioral activation
smoking cessation treatment for smokers with elevated depressive symptoms.
Journal of Consulting and Clinical Psychology, 78, 55-61.
Manos, R. C., Kanter, J. W., & Busch, A. M. (2010) A critical review of assessment
strategies to measure the behavioral activation model of depression. Clinical
Psychology Review, 30,547-561.
Martin, S. D., Martin, E., Rai, S. S., Richardson, M. A., & Royall, R. (2001). Brain blood
flow changes in depressed patients treated with interpersonal psychotherapy or
venlafaxine hydrochoride: Preliminary findings. Archives of General Psychiatry,
58, 641-648.
Mayberg, H. S. (2003). Modulating dysfunctional limbic-cortical circuits in depression:
Towards development of brain-based algorithms for diagnosis and optimized
treatment. British Medical Bulletin, 65, 193-207.
Mayberg, H. S. (2006). Defining neurocircuits in depression: Strategies toward treatment
selection based on neuroimgaing phenotypes. Psychiatric Annals, 36(4), 259–268.
Mayberg, H. S., Brannan, S. K., Mahurin, R. K., Jerabek, P. A., Brickman, J. S., Tekell,
J. L.,…Fox, P. (1997). Cingulate function in depression: A potential predictor of
treatment response. Neuroreport, 8, 1057-1061.
Mayberg, H. S., Brannan, S. K., Tekell, J. L., Silva, J. A., Mahurin, R. K., McGinnis, S.,
& Jerabek, P. A. (2000). Regional metabolic effects of fluoxetine in major
depression: Serial changes and relationship to clinical response. Biological
Psychiatry, 48, 830-843.
40

Mayberg, H. S., Liotti, M., Brannan S. K., McGinnis, S., Mahurin, R. K., Jerabek, P.
A.,…Fox, P. T. (1999). Reciprocal limbic-cortical function and negative mood:
Converging PET findings in depression and normal sadness. American Journal of
Psychiatry, 156, 675-682.
Mayberg, H. S., Lozano, A. M., Voon, V., McNeely, H. E., Seminowicz, D., Hamani,
C.,…Kennedy, S. H. (2005). Deep brain stimulation for treatment-resistant
depression. Neuron, 45, 651-660.
Mazzucchelli, T., Kane, R., & Rees, C. (2009). Behavioral activation treatments for depression
in adults: A meta-analysis and review. Clinical Psychology: Science and Practice. 16,
383-411.
Menon, V., & Levitin, D. J. (2005). The rewards of music listening: Response and
physiological connectivity of the mesolimbic system. Neuroimage, 28, 175-184.
Morin, C. M., Landreville, P., Colecchi, C., McDonald, K., Stone, J., & Ling, W. (1999).
The Beck Anxiety Inventory: Psychometric properties with older adults. Journal
of Clinical Geropsychology, 5, 19-29.
Mulick, P. S., & Naugle, A. E. (2004). Behavioral Activation for comorbid PTSD and
major depression: A case study. Cognitive and Behavioral Practice, 11, 378-387.
Mynors-Wallis, L. (2005). Problem-solving treatment for anxiety and depression: A
Practical guide. Oxford, UK: Oxford University Press.
Northoff, G., Heinzel, A., de Greck, M., Bermpohl, F., Dobrowolny, J., & Panksepp, J.
(2006). Self-referential processing in our brain: A meta-analysis of imaging
studies of the self. Neuroimage, 31, 440-457.

41

Ochsner, K. N., & Gross, J. G. (2005). The cognitive control of emotion. Trends in
Cognitive Sciences, 9, 242-249.
Oldfield, R. C. (1971). The assessment and analysis of handedness: The Edinburgh
Inventory. Neuropsychologia, 9(1), 97-113.
Osuch, E. A., Bluhm, R. L., Williamson, P. C., Theberge, J., Densmore, M., & Neufeld,
R. W. J. (2009). Brain activation to favorite music in healthy controls and
depressed patients. Neuroreport, 20(13), 1204-1208.
Pagoto, S., Bodenlos, J.S., Schneider, K.L., Olendzki, B., Spates, C.R., & Ma, Y. (2008). Initial
investigation of behavioral activation therapy for co-morbid major depressive disorder
and obesity. Psychotherapy: Theory, Research Practice, Training. 45, 410-415.
Pfaus, J. G., Damsma, G., Wenkstern, D., & Fibiger, H. C. (1995). Sexual activity
increases dopamine transmission in the nucleus accumbens and striatum of female
rats. Brain Research, 693(1-2), 21-30.
Phillips, M. L., Drevets, W. C., Rauch, S. L., & Lane, R. (2003). Neurobiology of
emotion perception II: Implications for major psychiatric disorders. Biological
Psychiatry, 54, 515-528.
Porter, J. F., Spates, C., & Smitham, S. S. (2004). Behavioral activation group therapy in
public mental health settings: A pilot investigation. Professional Psychology:
Research & Practice, 35, 297-301.
Schaefer, H.S., Putnam, K.M., Benca, R.B., & Davidson, R.J. (2006). Event-related
functional magnetic resonance imaging measures of neural activity to positive
social stimuli in pre- and post-treatment depression. Biological Psychiatry, 60,
974-986.
42

Schilström, B., Svensson, H. M., Svensson, T. H., & Nomikos, G. G. (1998). Nicotine
and food induced dopamine release in the nucleus accumbens of the rat: Putative
role of alpha7 nicotinic receptors in the ventral tegmental area. Neuroscience,
85(4), 1005-1009.
Shedler, J. (2010). The efficacy of psychodynamic psychotherapy. American
Psychologist, 65(2), 98-109.
Smoski, M. J., Felder, J., Bizzell, J., Green, S. R., Ernst, M., Lynch, T. R., & Dichter,
G.S. (2009). fMRI of alteration in reward selection, anticipation, and feedback in
major depressive disorder. Journal of Affective Disorders, 118(1-3), 69-78.
Sturmey, P. (2009). Behavioral activation is an evidence-based treatment for depression.
Behavior Modification. 33, 818-829.
Summers, R. F., & Barber, J. P. (2010). Psychodynamic psychotherapy: A guide to
evidence-based practice. New York, NY: The Guilford Press.
Watson, D., Clark, L. A., & Tellegen, A. (1988). Development and validation of brief
measures of positive and negative affect: The PANAS scales. Journal of
Personality and Social Psychology, 54, 1063-1070.
Welch, C. A., Czerwinski, D., Ghimire, B., Bertsimas, D. (2009). Depression and costs of
health care. Psychosomatics, 50(4), 392-401.
Wetherell, J. L., & Areán, P. A. (1997). Psychometric evaluation of the Beck Anxiety
Inventory with older medical patients. Psychological Assessment, 9, 136-144.
Wolf, N., & Hopko, D. R. (2008). Psychosocial and pharmacological interventions for
depressed adults in primary care: A critical review. Clinical Psychology Review,
28, 131-161.
43

Worsley. K. J. (1994). Local maxima and the expected Euler characteristic of excursion
sets of F and t fields. Advances in Applied Probability, 26, 13-42.

44

APPENDIX

45

Table 1
Symptom Measures At Pre-assessment and Post-treatment
_________________________________________________________________
BATD
PPP
_____________________
___________________
Measures
Pre
Post
Pre
Post
_________________________________________________________________

BDI-II

24

2

31

3

EROS

21

27

18

30

HAM-D

26

0

21

3

BAI

16

17

5

2

BIS

9

10

12

16

BAS-Drive

9

10

15

15

BAS-Fun

7

7

11

12

BAS-Reward Response

7

7

12

11

________________________________________________________________
Note. BATD = Behavioral Activation Treatment for Depression; PPP = Pragmatic
Psychodynamic Psychotherapy. All scores listed are raw scores.
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Table 2
BOLD response between pre- and post-treatment for BATD condition.
________________________________________________________________________
Region

Side

MNI
size p(cor) p(unc.) T-Value
x y z
________________________________________________________________________
Pre > Post (Pref. > Neu.)
Middle Frontal Gyrus
R
Frontal eye field/Dorsolateral PFC

42

17

31

35

.219

.016*

4.48

Inferior Frontal Gyrus
Medial orbital frontal

L

-27

35

-8

38

.178

.013*

4.09

Inferior Frontal Gyrus

R

24

32

-20

18

.663

.070

4.23

-3

35

-20

79

.012**

.001*

4.73

Medial orbital Frontal

Post>Pre (Music > Slience)
Subgenual cingulate/moPFC
Inferior Frontal Gyrus

L

-51 38

16

36

.204

.015*

4.37

R

21

32

-20

27

.379

.031*

4.73

L

-36 44

19

46

.102

.007*

4.32

Dorsolateral PFC
Middle Frontal Gyrus
Medial orbital frontal

Pre>Post (Music > Slience)
Middle Frontal Gyrus
Lateral Anterior frontal PFC

________________________________________________________________________
Note. MNI corresponds to Montreal Neurological Institute coordinates. Size corresponds
to the number of voxels within a given activation cluster, where T-Value denotes peak TValue activation within that cluster. Significance at the p-corrected level of .05 is denoted
by ** where significance at the p-uncorrected level of .05 is denoted by *.
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Table 3
BOLD response between pre- and post-treatment for PPP condition
________________________________________________________________________
Region

Side

MNI
size p(cor) p(unc.) T-Value
x y z
________________________________________________________________________
Pre>Post (Neu. > Pref)
R

9

41

-20

21

.546

.05*

4.05

L

-33

56

-2

33

.241

.017*

3.85

R

36

47

25

36

.194

.014*

3.60

Superior Frontal Gyrus

L

-3

53

13

103

<.001** .003*

3.67

Middle Frontal Gyrus

L

-24 29

-17

27

.367

.029*

3.61

L

-48 11

46

21

.546

.05*

3.47

-23

167

<.001** <.001*

Medial Frontal Gyrus
Medial orbital frontal

Pre>Post (Pref. > Neu.)
Middle Frontal Gyrus
Dorsolateral PFC
Middle Fontal Gyrus
Dorsolateral PFC

Pre>Post (Music – Slience)

Lateral orbital frontal PFC
Middle Frontal Gyrus
Frontal eye field/Dorsolateral PFC
Subgenual Cingulate

0

29

4.91

________________________________________________________________________
Note. MNI corresponds to Montreal Neurological Institute coordinates. Size corresponds
to the number of voxels within a given activation cluster, where T-Value denotes peak TValue activation within that cluster. Significance at the p-corrected value of .05 is
denoted by ** where significance at the p-uncorrected value of .05 is denoted by *.
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Figure 1. Visual Representation of Block Design completed by participants during their
30 minute functional MRI scan prior to an following their treatment. P1 denotes the first
50 seconds of the preferred music passage where P2 and P3 denotes 51 through 1.40
seconds and 1.41 through 2.30 seconds of that preferred song. N denotes neutral music
passages, S to silence, and s to seconds.

Figure 2. BDI-II scores completed at pre-assessment, during each of the 8 therapy
sessions, and following completion of BATD.

Figure 3. EROS scores completed at pre-assessment, during each of the 8 therapy
sessions, and following completion of BATD.
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Figure 4. BDI-II scores completed at pre-assessment, during each of the 8 therapy
sessions, and following completion of PPP.

Figure 5. EROS scores completed at pre-assessment, during each of the 8 therapy
sessions, and following completion of PPP.

Figure 6. Cross-correlational analyses of EROS and BDI-II from pre-assessment, though
each of the 8 therapy sessions, and following completion of BATD. CCA statistics for the
patient receiving BATD showed that the BDI-II and EROS scores were statistically
significant at lag 0 (r = -0.92, p = 0.000).
50

Figure 7. Cross-correlational analyses (CCA) of EROS and BDI-II from pre-assessment,
though each of the 8 therapy sessions, and following completion of PPP. CCA statistics
for the patient receiving PPP showed that the BDI-II and EROS scores were statistically
significant at lag 0 (r=-0.90, p = 0.001).
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A.

B.

C.
Figure 8. T-Maps and plots denoting BOLD response for interaction contrast of treatment (pre, post) by
music (preferred, neutral) for BATD. Contrasts denote that BOLD response was indistinguishable between
preferred and neutral pre-treatment in the (A) right dorsolateral cortex (42 17 31) and (B) left medial orbital
frontal cortex (-27 35 -8) where each region evidenced elevated BOLD response during preferred, relative
to neutral, at post-treatment. BOLD response was deactive in the (C) right medial orbital frontal cortex (24
32 -20) during preferred music, relative to neutral, at pre-treatment, and evidenced elevated BOLD
response during preferred, relative to neutral, at post-treatment. Neurological convention (right on right) is
used and coordinates are in Montreal Neurological Institute space.
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A.

B.

C.

D.
Figure 9. T-Maps and plots denoting BOLD response for interaction contrast of treatment (pre, post) by
music, agnostic to valence (music, silence) for BATD. Contrasts denote that pre-treatment BOLD
responses were deactive for music, relative silence, within the (A) subgenual cingulate (-3 35 -20), the (B)
left dorsolateral prefrontal cortex (-51 38 16), and the (C) right medial orbital frontal cortex (21 32 -20),
and, at post-treatment, these regions trended towards higher BOLD response for music, relative to silence,
though, the activations evidenced little distinctiveness between music and silence at post-treatment. BOLD
response was slightly elevated in the (D) left lateral anterior frontal cortex (-36 44 19) during music,
relative silence, at pre-treatment and was deactive during music, relative to silence, at post-treatment.
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A.

B.

C.
Figure 10. T-Maps and plots denoting BOLD response for interaction contrast of treatment (pre, post) by
music (preferred, neutral) for PPP. Contrasts denote that BOLD response was indistinguishable between
preferred and neutral pre-treatment in the (A) right medial orbital (9 -41 -20) and (B) left lateral anterior
PFC (-33 56 -2) where it evidenced elevated BOLD response and decreased BOLD response, relative to
neutral, in these respective areas at post-treatment. BOLD response was slightly elevated in for preferred
music, relative to neutral, at pre-treatment, and was deactive during preferred, relative to neutral, at posttreatment in the (C) right dorsolateral prefrontal cortex (36 47 25).
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A.

B.

C.

D.
Figure 11. T-Maps and plots denoting BOLD response for interaction contrast of treatment (pre, post) by
music, agnostic to valence (music, silence) for PPP. Contrasts denote that BOLD response elevated for
music, relative silence, at pre-treatment within the left sided (A) medial anterior frontal (-3 53 13), the (C)
dorsolateral PFC (-48 11 46), and the (D) subgenual cingulate (0 29 -23), and was deactive in these regions,
during music relative silence, at post-treatment. BOLD response was indistinguishable between music and
silence at pre-treatment within the (B) left ventral medial frontal cortex (-24 29 13) and was more deactive
during music, relative silence, at post-treatment.
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